瑪麗安Liebert于1980年創(chuàng)立,Mary Ann Liebert inc .是一家獨立出版商的科學(xué)、技術(shù)、和醫(yī)學(xué)內(nèi)容,聞名于世,其先見之明和建立權(quán)威的同行評議期刊,書籍,和貿(mào)易出版物在尖端領(lǐng)域如生物技術(shù)、生物醫(yī)學(xué)研究、醫(yī)學(xué)和手術(shù),公共衛(wèi)生研究和政策、技術(shù)、工程、法律、環(huán)境研究和政策,和其他專業(yè)學(xué)科。該公司出版超過90種同行評審期刊，領(lǐng)先的行業(yè)雜志，專業(yè)通訊，除了社會成員管理和會議。瑪麗·安·利伯特(Mary Ann Liebert)以其遠(yuǎn)見卓識的激情和永不停歇的好奇心為動力，通過創(chuàng)建面向市場的專業(yè)出版物來識別和培育關(guān)鍵主題和前沿領(lǐng)域，這些出版物在推進(jìn)研究和促進(jìn)學(xué)術(shù)界、產(chǎn)業(yè)界和政府的合作方面發(fā)揮著至關(guān)重要的作用。該公司致力于確保最高質(zhì)量的內(nèi)容，并有能力長期投資，支持新興市場的出版物直至成熟。該公司的旗艦出版物《基因工程與生物技術(shù)新聞》(GEN)于1980年發(fā)行，是生物技術(shù)領(lǐng)域的第一本同類出版物。今天，GEN是該領(lǐng)域最廣泛閱讀和高度評價的出版物，提供最前沿的新聞和分析技術(shù)、應(yīng)用和趨勢，推動生物技術(shù)的未來。自生物技術(shù)誕生以來，GEN一直處于該領(lǐng)域的最前沿，保持著無與倫比的完整性、影響力和專業(yè)知識，在推動行業(yè)生產(chǎn)力和增長方面發(fā)揮著關(guān)鍵作用。該公司在市場上發(fā)表了許多“第一”，包括艾滋病研究和人類逆轉(zhuǎn)錄病毒，人類基因治療，LGBT健康，以及最近的CRISPR雜志。Mary Ann Liebert, Inc.為作者、圖書館和機構(gòu)提供了快速和靈活的模型，使發(fā)布內(nèi)容能夠快速傳播和高可視性。該公司的使命是推進(jìn)研究和開發(fā)，促進(jìn)合作，使最佳治療方案成為可能，并最終改善病人護(hù)理。Mary Ann Liebert, Inc.不僅僅是一個出版商，還與企業(yè)、教育機構(gòu)、非營利基金會和其他企業(yè)進(jìn)行有效的合作，包括定制出版物、會議、網(wǎng)絡(luò)研討會、協(xié)會管理、視頻和時事通訊。這些資源對于公司、協(xié)會和機構(gòu)推進(jìn)自己的目標(biāo)發(fā)揮著關(guān)鍵作用。瀏覽我們的出版物，探索我們已建立的期刊的內(nèi)容，并了解更多關(guān)于我們廣泛的能力。一如既往，瑪麗安歡迎您的反饋和意見，并致力于繼續(xù)滿足世界各地學(xué)術(shù)界、政府和工業(yè)界——包括公共和私營部門——的需求。

Founded by Mary Ann Liebert in 1980, Mary Ann Liebert, Inc. is a leading independent publisher of scientific, technical, and medical content, known worldwide for its prescience and establishment of authoritative peer-reviewed journals, books, and trade publications in cutting-edge fields such as biotechnology, biomedical research, medicine and surgery, public health research and policy, technology and engineering, law, environmental research and policy, and other specialized disciplines. The company publishes over 90 peer-reviewed journals, leading trade magazines, and specialized newsletters, in addition to society membership management and conferences.Driven by her visionary passion and ceaseless curiosity, Mary Ann Liebert identifies and nurtures critical topics and cutting-edge fields by creating first-to-market, specialized publications that play a vital role in advancing research and facilitating collaboration in academia, industry, and government. The company is deeply committed to ensuring the highest quality content and is able to invest for the long-term, supporting publications in emerging markets through to maturity.The company’s flagship publication, Genetic Engineering & Biotechnology News (GEN), was launched in 1980, the very first publication of its kind for the field of biotechnology. Today, GEN is the most widely read and highly regarded publication in the field, delivering cutting-edge news and analysis of the technologies, applications, and trends that are driving the future of biotechnology. GEN has been at the forefront of the field since the birth of biotech, maintaining unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry.The company has published many “firsts” in the market, including AIDS Research and Human Retroviruses, Human Gene Therapy, LGBT Health, and, most recently, The CRISPR Journal.Mary Ann Liebert, Inc. provides fast and flexible models for authors, libraries, and institutions that enable rapid dissemination and high visibility of published content. The company’s mission is to advance research and development, foster collaborations that enable best therapeutic options, and, ultimately, to improve patient care.More than just a publisher, Mary Ann Liebert, Inc. collaborates effectively with corporations, educational institutions, nonprofit foundations, and other enterprises in a broad array of extended capabilities that include custom publications, conferences, webinars, association management, videos, and newsletters. These resources play a pivotal role for corporations, associations, and institutions to advance their own goals.Browse our publications, explore the content of our established journals, and learn more about our extensive capabilities. As always, Mary Ann welcomes your feedback and input, and is committed to continuing to meet the needs of the members of academia, government, and industry—in the public and private sectors—around the world.